ArticleNature immunology2020
Bidirectional signals of PD-L1 in T cells that fraternize with cancer cells.
Article in Nature immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- Bi-directional regulation between NAD/NAMPT and IFN-γ/PD-L1 axes via BRD4/IRF1 and mitochondrial respiration in metastatic cutaneous melanoma.Journal of experimental & clinical cancer research : CR · 2026Article
- PD-L1 cell-intrinsic signals limit immune activation during cutaneous vaccinia virus infection.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Potential CD27-CD70 interaction within adoptive T cells does not affect tumor antigen-specific T-cell immunotherapy.ImmunoHorizons · 2026Article
- Reading the immune clock: a machine learning model predicts mouse immune age from cellular patterns.Nature communications · 2025Article
- Validation of CCL20-driven CAR-γδ T secreting PD-1 blockade with enhanced trafficking into solid tumor.iScience · 2025Article
- Innovative PDK1-Degrading PROTACs Transform Cancer Aerobic Glycolysis and Induce Immunogenic Cell Death in Breast Cancer.Exploration (Beijing, China) · 2025Article
- Mechanisms and clinical advancements of cell-based immunotherapies in non-small cell lung cancer: an integrated perspective.Frontiers in immunology · 2025Review
- Prognostic value of tumor-infiltrating lymphocytes and PD-L1 expression in esophageal squamous cell carcinoma.Cancer medicine · 2024Article
- Regulation of Tumor Dendritic Cells by Programmed Cell Death 1 Pathways.Journal of immunology (Baltimore, Md. : 1950) · 2024Review
- Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Blocking of programmed cell death-ligand 1 (PD-L1) expressed on endothelial cells promoted the recruitment of CD8Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Article
- Emerging phagocytosis checkpoints in cancer immunotherapy.Signal transduction and targeted therapy · 2023Review
- A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration-Approved PD-1 and PD-L1 Inhibitors.ImmunoHorizons · 2023Article
- Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment.Journal for immunotherapy of cancer · 2022Article
- Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.Frontiers in immunology · 2022Review
- Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models.Journal for immunotherapy of cancer · 2022Article
- Not Only Immune Escape-The Confusing Role of the TRP Metabolic Pathway in Carcinogenesis.Cancers · 2021Review
- Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.Cancer immunology, immunotherapy : CII · 2021Review
- Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance.International journal of molecular sciences · 2020Review
- PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy.International journal of molecular sciences · 2020Review
Corrections and comments
- Comment on
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.